Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Advanced Targeted Drug Delivery of Bioactive Nanomaterials in the Management of Cancer

In Press, (this is not the final "Version of Record"). Available online 16 February, 2024
Author(s): Biswajit Basu, Kevin Kumar Garala, Rajeshri Patel, Ayon Dutta, Dipanjana Ash, Bhupendra Prajapati*, Sudarshan Singh and Sajal Kumar Jha
Published on: 16 February, 2024

DOI: 10.2174/0109298673283362231220115050

Price: $95

Abstract

Cancer is defined as the unchecked expansion of aberrant cells. Radiation, chemotherapy, and surgery are currently used in combination to treat cancer. Traditional drug delivery techniques kill healthy proliferating cells when used over prolonged periods of time in cancer chemotherapy. Due to the fact that the majority of tumor cells do not infiltrate right away, this is particularly true when treating solid tumors. A targeted drug delivery system (TDDS) is a tool that distributes medication to a selected bioactive location in a controlled manner. Nanotechnology-based delivery techniques are having a substantial impact on cancer treatment, and polymers are essential for making nanoparticulate carriers for cancer therapy. The advantages of nanotherapeutic drug delivery systems (NDDS) in terms of technology include longer half-life, improved biodistribution, longer drug circulation time, regulated and sustained drug release, flexibility in drug administration method, higher drug intercellular concentration, and others. The benefits and drawbacks of cancer nanomedicines, such as polymer-drug conjugates, micelles, dendrimers, immunoconjugates, liposomes, and nanoparticles, are discussed in this work, along with the most recent findings on polymer-based anticancer drugs.

Keywords: Bioactive nanomaterials, cancer, targeted drug delivery system, nano formulations.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy